# Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 19-40 y

> **NCT00698906** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 160 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** HBV-MPL vaccine
- **BIOLOGICAL:** Engerix™-B

## Key facts

- **NCT ID:** NCT00698906
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-06
- **Primary completion:** 1998-02
- **Final completion:** —
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2008-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00698906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00698906, "Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 19-40 y". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00698906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*